Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India. The AIM-traded firm said the newly-granted patent in India encompassed both the composition of matter patent for the Nuvec particle itself, and the associated manufacturing process.

It said the achievement aligned with previously-granted patents in various regions, including the US, Canada, Europe, Japan, Australia and China.

"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec," said chief executive officer Nigel Theobald.

At 1111 GMT, shares in N4 Pharma were up 3.09% at 1p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Agronomics investee Solar Foods raises EUR 8m
(Sharecast News) - Cellular agriculture investor Agronomics announced on Friday that its portfolio company Solar Foods had raised an additional €8m through Finnish investment organiser Springvest.
Berenberg hikes target price on Greggs
(Sharecast News) - Analysts at Berenberg raised their target price on bakery chain Greggs from 3,550.0p to 3,990.0p on Friday as it noted that customer appeal had broadened as its market share was expanding.
Thousands of UK firms fighting for survival - Begbies Traynor
(Sharecast News) - More than half a million UK business are fighting for survival, according to an industry research published on Friday, weighed down by the weak economy.
Thruvision FY24 adjusted underlying losses widen
(Sharecast News) - Security technology business Thruvision said on Friday that adjusted underlying losses had widened in FY24 as revenues fell.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.